U.S. Medical Equipment Stock News

Over the last 7 days, the United States market has experienced a 2.3% drop, yet it remains up by 13% over the past year with earnings projected to grow by 16% annually. In this context, identifying stocks that are trading below their intrinsic value can present opportunities for investors seeking to capitalize on potential long-term gains amidst fluctuating market conditions.

The recent 13% drop in Indaptus Therapeutics, Inc.'s ( NASDAQ:INDP ) stock could come as a blow to insiders who...

Over the last 7 days, the United States market has experienced a 2.3% drop, yet it has shown resilience with a 13% rise over the past year and earnings are expected to grow by 16% annually. In such dynamic conditions, dividend stocks can offer investors stability and income potential, making them an attractive option for those seeking steady returns amidst market fluctuations.

Insiders who bought US$1.73m worth of Cartesian Therapeutics, Inc.'s ( NASDAQ:RNAC ) stock at an average buy price of...

We feel now is a pretty good time to analyse CollPlant Biotechnologies Ltd.'s ( NASDAQ:CLGN ) business as it appears...

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...

Usually, when one insider buys stock, it might not be a monumental event. But when multiple insiders are buying like...

The Morning Bull - US Market Morning Update Wednesday, Mar, 25 2026 US stock futures are pointing higher this morning, with key contracts on the S&P 500 and Nasdaq up around 1%, as investors weigh easing tensions in the Middle East against stubbornly high borrowing costs. The US 10 year Treasury yield is sitting above 4.4%, an eight month high, which means mortgages, car loans and business financing remain expensive. At the same time, fresh US business surveys show manufacturing at 52.4 and...

Fennec Pharmaceuticals (FENC) just posted its FY 2025 third quarter numbers, with revenue of US$12.5 million and a basic EPS loss of US$0.02, while net income excluding extra items came in at a loss of US$0.6 million. Over recent quarters the company has seen revenue move from US$7.3 million in Q2 FY 2024 to US$9.7 million in Q2 FY 2025 and then to US$12.5 million in Q3 FY 2025. Over the same period, basic EPS shifted from a loss of US$0.20 in Q2 FY 2024 to a loss of US$0.11 in Q2 FY 2025 and...

The US government has launched a multi trillion dollar consortium to support critical semiconductor and advanced manufacturing supply chains as part of an expanded Pax Silica program. The initiative aims to channel substantial funding into domestic fabrication, tooling, industrial lasers and related infrastructure over the medium term. IPG Photonics, listed as NasdaqGS:IPGP, sits within the industrial laser segment that is closely tied to these manufacturing and semiconductor build...

If you are wondering whether National Beverage at around US$33.71 is a bargain or a value trap, this breakdown will help you connect the share price to what the business may be worth. The stock is up 6.5% year to date, although it has seen a 2.6% slip over the last week and an 8.9% decline over the last month. The 1 year return of 16.1% and 3 year return of 31.2% highlight how sentiment has shifted over time. Recent coverage has focused on National Beverage's position in the soft drinks...

Veracyte, NasdaqGM:VCYT, has appointed Kevin Haas, Ph.D., as Chief Development and Technology Officer in a newly created executive role. Dr. Haas will oversee assay development, software, AI, and next generation informatics across Veracyte's product pipeline. The move reflects Veracyte's focus on whole genome MRD and multi omics applications across its global portfolio. Veracyte's share price stands at $32.94, with a return of 60.1% over the past 3 years and a 2.2% decline over the past...

Janus Living (NYSE:JAN) has arranged $600 million in new unsecured credit facilities. The package includes a $500 million unsecured revolving credit facility and a $100 million unsecured delayed draw term loan facility. The new funding is intended to increase liquidity and support future expansion plans. For investors watching NYSE:JAN, the new credit facilities arrive with the stock at $23.75 and a year-to-date return of 0.6%. The move reshapes Janus Living's funding options as a REIT and...

Perma-Fix Environmental Services (PESI) FY 2025 earnings snapshot Perma-Fix Environmental Services (PESI) reported third quarter FY 2025 revenue of US$17.5 million with a basic EPS loss of US$0.10, while trailing twelve month EPS stood at a loss of US$0.64 on revenue of US$60.7 million. This highlights that the business remains in loss making territory. Over recent quarters, revenue has ranged from US$13.9 million to US$17.5 million, while quarterly EPS losses have moved between US$0.09 and...

If you are wondering whether AvePoint's current share price lines up with its underlying worth, this breakdown will help you make sense of what the market is implying. The stock recently closed at US$9.61, with returns of 8.4% decline over 7 days, 8.5% decline over 30 days, 27.3% decline year to date, 36.9% decline over 1 year, 146.4% gain over 3 years, and 13.3% decline over 5 years, so the recent share price path has been mixed across different time frames. Recent news coverage has focused...

Investors may be wondering if Webster Financial at around US$68.67 is offering reasonable value today, or if the recent run has already priced in the upside. The stock is up 34.0% over the past year and 93.1% over three years, with a 7.6% gain year to date, even though it has seen a 6.0% decline over the last month and a small 0.3% move over the past week. Recent attention on banks listed on the New York Stock Exchange has put valuation and balance sheet quality back in focus, and Webster...

Recent Results Set the Stage for Battalion Oil’s Next Chapter Battalion Oil (BATL) just posted its latest FY 2025 numbers with Q3 revenue of US$43.5 million and a basic EPS loss of US$0.91, alongside trailing twelve month revenue of US$183.4 million and a basic EPS loss of US$3.35. Over the past few quarters, total revenue has moved between US$42.8 million and US$49.7 million while quarterly basic EPS has ranged from a loss of US$1.88 to a profit of US$0.34. This gives investors a mixed read...

Cardinal Infrastructure Group (CDNL) just closed FY 2025 with fourth quarter revenue of US$145.8 million and net income of US$2.9 million, translating to EPS of about US$0.20. Over the past year, the company has seen trailing 12 month revenue move from US$315.2 million to US$456.0 million, while trailing net margin sits at 5% compared with 6.8% a year earlier, setting a clear context for how profitability is tracking against growth. For investors, this mix of higher top line and softer...

Latest FY 2025 Results: Revenue Pressure and Deep Losses at Sutro Biopharma (STRO) Sutro Biopharma (STRO) has put out fresh FY 2025 numbers, with Q3 total revenue of US$9.7 million, a basic EPS loss of US$6.70, and net income loss excluding extra items of US$56.9 million setting the tone for the update. The company has seen quarterly revenue move between US$8.5 million and US$63.7 million over the last six reported periods, while basic EPS has ranged from a loss of US$1.36 to a loss of...

Wondering if Reliance at around US$300.22 is offering value or asking you to pay up for quality is exactly the question this breakdown will help you tackle. The stock is up 0.4% over the last 7 days and 1.5% year to date, but a 5.9% pullback over the past month sits against a 4.1% 1 year return, 22.8% over 3 years and 115.4% over 5 years. Recent coverage has focused on Reliance as a long term Metals and Mining name. Investor attention has been drawn to how its multi year share performance...

BioAge Labs (BIOA) just posted its FY 2025 third quarter numbers, reporting revenue of US$2.1 million and a basic EPS loss of US$0.56, alongside a net loss of US$20.2 million, keeping the story firmly in loss-making territory. Over recent quarters, revenue has moved from US$0 million in Q4 2024 to US$1.5 million in Q1 2025 and US$2.4 million in Q2 2025. Quarterly basic EPS has remained in loss-per-share territory between US$0.36 and US$0.60, which keeps the focus on the pace at which losses...

Sanara MedTech (SMTI) just posted its latest FY 2025 numbers, with Q3 revenue at US$26.3 million and basic EPS of US$0.10 from continuing operations, while trailing twelve month figures show revenue of US$101.9 million and a basic EPS loss of US$0.71. Over recent quarters the company has seen revenue range from US$20.2 million to US$26.3 million and quarterly basic EPS swing between a loss of US$0.41 and a profit of US$0.10, with trailing twelve month earnings from discontinued operations...

Wondering whether ArcBest at around US$94.60 is offering value right now or asking too much of future expectations? This article breaks down what the current price could be telling you. The share price has moved 10.1% over the last 7 days, while the 30 day return stands at a 10.0% decline and the 1 year return is 29.7%, with 22.6% year to date. Recent news coverage has focused on ArcBest as a transportation and logistics player in a sector that often reacts quickly to shifts in freight...

Financial results set the stage for LENZ Therapeutics (LENZ) LENZ Therapeutics (LENZ) has reported fresh numbers for FY 2025, with third quarter revenue of US$12.5 million and a loss per share of US$0.59, as net income excluding extra items came in at a loss of US$16.7 million. The company’s revenue moved from US$0 in the second quarter of 2024 to US$12.5 million in the third quarter of 2025. Over the same period, basic EPS shifted from a loss of US$0.38 to a loss of US$0.59. This provides a...